What is the current valuation of the Adeno-associated Virus (AAV) Vector-based Gene Therapy Market?

The market valuation was 5.718 USD Billion in 2024. Read More

What is the projected market size for the AAV Vector-based Gene Therapy Market by 2035?

The projected valuation for 2035 is 70.67 USD Billion. Read More

What is the expected CAGR for the AAV Vector-based Gene Therapy Market during the forecast period?

The expected CAGR for the market from 2025 to 2035 is 25.68%. Read More

Which disease types are leading in the AAV Vector-based Gene Therapy Market?

Hematological malignancies and neurological disorders are leading, with valuations of 18.0 and 15.0 USD Billion, respectively. Read More

What are the key vector serotypes in the AAV Vector-based Gene Therapy Market?

AAV8 and AAV2 are key serotypes, with projected valuations of 18.0 and 15.0 USD Billion, respectively. Read More

How does the administration route impact the AAV Vector-based Gene Therapy Market?

Intravenous administration is projected to lead with a valuation of 18.0 USD Billion. Read More

Who are the major players in the AAV Vector-based Gene Therapy Market?

Key players include Spark Therapeutics, Bayer AG, Novartis AG, and Bristol-Myers Squibb. Read More

What is the market performance of oncology within the AAV Vector-based Gene Therapy Market?

Oncology is projected to reach a valuation of 15.67 USD Billion. Read More

How do the projected growth rates vary among different disease types in the AAV Vector-based Gene Therapy Market?

Hematological malignancies and neurological disorders show the highest growth potential, indicating robust market dynamics. Read More

What implications do the growth projections have for investment in the AAV Vector-based Gene Therapy Market?

The substantial projected growth suggests a favorable environment for investment, particularly from leading companies. Read More

Adeno Associated Virus Aav Vector Based Gene Therapy Market

ID: MRFR/HC/27946-HCR

128 Pages

Nidhi Mandole

Last Updated: April 06, 2026

Adeno-associated Virus (AAV) Vector-based Gene Therapy Market Research Report: Size, Share, Trend Analysis By Disease Type (Hematological Malignancies, Neurological Disorders, Cardiovascular Diseases, Ophthalmic Diseases, Oncology), By Vector Serotype (AAV1, AAV2, AAV5, AAV6, AAV8, AAV9), By Administration Route (Intravenous, Intramuscular, Subcutaneous, Intraocular, Intracerebral) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Adeno Associated Virus Aav Vector Based Gene Therapy Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Disease Type (USD Billion)
  1. 4.1.1 Hematological Malignancies
  2. 4.1.2 Neurological Disorders
  3. 4.1.3 Cardiovascular Diseases
  4. 4.1.4 Ophthalmic Diseases
  5. 4.1.5 Oncology
2. 4.2 Healthcare, BY Vector Serotype (USD Billion)
  1. 4.2.1 AAV1
  2. 4.2.2 AAV2
  3. 4.2.3 AAV5
  4. 4.2.4 AAV6
  5. 4.2.5 AAV8
  6. 4.2.6 AAV9
3. 4.3 Healthcare, BY Administration Route (USD Billion)
  1. 4.3.1 Intravenous
  2. 4.3.2 Intramuscular
  3. 4.3.3 Subcutaneous
  4. 4.3.4 Intraocular
  5. 4.3.5 Intracerebral
4. 4.4 Healthcare, BY Region (USD Billion)
  1. 4.4.1 North America
    1. 4.4.1.1 US
    2. 4.4.1.2 Canada
  2. 4.4.2 Europe
    1. 4.4.2.1 Germany
    2. 4.4.2.2 UK
    3. 4.4.2.3 France
    4. 4.4.2.4 Russia
    5. 4.4.2.5 Italy
    6. 4.4.2.6 Spain
    7. 4.4.2.7 Rest of Europe
  3. 4.4.3 APAC
    1. 4.4.3.1 China
    2. 4.4.3.2 India
    3. 4.4.3.3 Japan
    4. 4.4.3.4 South Korea
    5. 4.4.3.5 Malaysia
    6. 4.4.3.6 Thailand
    7. 4.4.3.7 Indonesia
    8. 4.4.3.8 Rest of APAC
  4. 4.4.4 South America
    1. 4.4.4.1 Brazil
    2. 4.4.4.2 Mexico
    3. 4.4.4.3 Argentina
    4. 4.4.4.4 Rest of South America
  5. 4.4.5 MEA
    1. 4.4.5.1 GCC Countries
    2. 4.4.5.2 South Africa
    3. 4.4.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Spark Therapeutics (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bayer AG (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Novartis AG (CH)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Bristol-Myers Squibb (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 GSK (GB)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Pfizer Inc. (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Sarepta Therapeutics (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Astellas Pharma Inc. (JP)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 UniQure N.V. (NL)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY DISEASE TYPE
4. 6.4 US MARKET ANALYSIS BY VECTOR SEROTYPE
5. 6.5 US MARKET ANALYSIS BY ADMINISTRATION ROUTE
6. 6.6 CANADA MARKET ANALYSIS BY DISEASE TYPE
7. 6.7 CANADA MARKET ANALYSIS BY VECTOR SEROTYPE
8. 6.8 CANADA MARKET ANALYSIS BY ADMINISTRATION ROUTE
9. 6.9 EUROPE MARKET ANALYSIS
10. 6.10 GERMANY MARKET ANALYSIS BY DISEASE TYPE
11. 6.11 GERMANY MARKET ANALYSIS BY VECTOR SEROTYPE
12. 6.12 GERMANY MARKET ANALYSIS BY ADMINISTRATION ROUTE
13. 6.13 UK MARKET ANALYSIS BY DISEASE TYPE
14. 6.14 UK MARKET ANALYSIS BY VECTOR SEROTYPE
15. 6.15 UK MARKET ANALYSIS BY ADMINISTRATION ROUTE
16. 6.16 FRANCE MARKET ANALYSIS BY DISEASE TYPE
17. 6.17 FRANCE MARKET ANALYSIS BY VECTOR SEROTYPE
18. 6.18 FRANCE MARKET ANALYSIS BY ADMINISTRATION ROUTE
19. 6.19 RUSSIA MARKET ANALYSIS BY DISEASE TYPE
20. 6.20 RUSSIA MARKET ANALYSIS BY VECTOR SEROTYPE
21. 6.21 RUSSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
22. 6.22 ITALY MARKET ANALYSIS BY DISEASE TYPE
23. 6.23 ITALY MARKET ANALYSIS BY VECTOR SEROTYPE
24. 6.24 ITALY MARKET ANALYSIS BY ADMINISTRATION ROUTE
25. 6.25 SPAIN MARKET ANALYSIS BY DISEASE TYPE
26. 6.26 SPAIN MARKET ANALYSIS BY VECTOR SEROTYPE
27. 6.27 SPAIN MARKET ANALYSIS BY ADMINISTRATION ROUTE
28. 6.28 REST OF EUROPE MARKET ANALYSIS BY DISEASE TYPE
29. 6.29 REST OF EUROPE MARKET ANALYSIS BY VECTOR SEROTYPE
30. 6.30 REST OF EUROPE MARKET ANALYSIS BY ADMINISTRATION ROUTE
31. 6.31 APAC MARKET ANALYSIS
32. 6.32 CHINA MARKET ANALYSIS BY DISEASE TYPE
33. 6.33 CHINA MARKET ANALYSIS BY VECTOR SEROTYPE
34. 6.34 CHINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
35. 6.35 INDIA MARKET ANALYSIS BY DISEASE TYPE
36. 6.36 INDIA MARKET ANALYSIS BY VECTOR SEROTYPE
37. 6.37 INDIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
38. 6.38 JAPAN MARKET ANALYSIS BY DISEASE TYPE
39. 6.39 JAPAN MARKET ANALYSIS BY VECTOR SEROTYPE
40. 6.40 JAPAN MARKET ANALYSIS BY ADMINISTRATION ROUTE
41. 6.41 SOUTH KOREA MARKET ANALYSIS BY DISEASE TYPE
42. 6.42 SOUTH KOREA MARKET ANALYSIS BY VECTOR SEROTYPE
43. 6.43 SOUTH KOREA MARKET ANALYSIS BY ADMINISTRATION ROUTE
44. 6.44 MALAYSIA MARKET ANALYSIS BY DISEASE TYPE
45. 6.45 MALAYSIA MARKET ANALYSIS BY VECTOR SEROTYPE
46. 6.46 MALAYSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
47. 6.47 THAILAND MARKET ANALYSIS BY DISEASE TYPE
48. 6.48 THAILAND MARKET ANALYSIS BY VECTOR SEROTYPE
49. 6.49 THAILAND MARKET ANALYSIS BY ADMINISTRATION ROUTE
50. 6.50 INDONESIA MARKET ANALYSIS BY DISEASE TYPE
51. 6.51 INDONESIA MARKET ANALYSIS BY VECTOR SEROTYPE
52. 6.52 INDONESIA MARKET ANALYSIS BY ADMINISTRATION ROUTE
53. 6.53 REST OF APAC MARKET ANALYSIS BY DISEASE TYPE
54. 6.54 REST OF APAC MARKET ANALYSIS BY VECTOR SEROTYPE
55. 6.55 REST OF APAC MARKET ANALYSIS BY ADMINISTRATION ROUTE
56. 6.56 SOUTH AMERICA MARKET ANALYSIS
57. 6.57 BRAZIL MARKET ANALYSIS BY DISEASE TYPE
58. 6.58 BRAZIL MARKET ANALYSIS BY VECTOR SEROTYPE
59. 6.59 BRAZIL MARKET ANALYSIS BY ADMINISTRATION ROUTE
60. 6.60 MEXICO MARKET ANALYSIS BY DISEASE TYPE
61. 6.61 MEXICO MARKET ANALYSIS BY VECTOR SEROTYPE
62. 6.62 MEXICO MARKET ANALYSIS BY ADMINISTRATION ROUTE
63. 6.63 ARGENTINA MARKET ANALYSIS BY DISEASE TYPE
64. 6.64 ARGENTINA MARKET ANALYSIS BY VECTOR SEROTYPE
65. 6.65 ARGENTINA MARKET ANALYSIS BY ADMINISTRATION ROUTE
66. 6.66 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE TYPE
67. 6.67 REST OF SOUTH AMERICA MARKET ANALYSIS BY VECTOR SEROTYPE
68. 6.68 REST OF SOUTH AMERICA MARKET ANALYSIS BY ADMINISTRATION ROUTE
69. 6.69 MEA MARKET ANALYSIS
70. 6.70 GCC COUNTRIES MARKET ANALYSIS BY DISEASE TYPE
71. 6.71 GCC COUNTRIES MARKET ANALYSIS BY VECTOR SEROTYPE
72. 6.72 GCC COUNTRIES MARKET ANALYSIS BY ADMINISTRATION ROUTE
73. 6.73 SOUTH AFRICA MARKET ANALYSIS BY DISEASE TYPE
74. 6.74 SOUTH AFRICA MARKET ANALYSIS BY VECTOR SEROTYPE
75. 6.75 SOUTH AFRICA MARKET ANALYSIS BY ADMINISTRATION ROUTE
76. 6.76 REST OF MEA MARKET ANALYSIS BY DISEASE TYPE
77. 6.77 REST OF MEA MARKET ANALYSIS BY VECTOR SEROTYPE
78. 6.78 REST OF MEA MARKET ANALYSIS BY ADMINISTRATION ROUTE
79. 6.79 KEY BUYING CRITERIA OF HEALTHCARE
80. 6.80 RESEARCH PROCESS OF MRFR
81. 6.81 DRO ANALYSIS OF HEALTHCARE
82. 6.82 DRIVERS IMPACT ANALYSIS: HEALTHCARE
83. 6.83 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
84. 6.84 SUPPLY / VALUE CHAIN: HEALTHCARE
85. 6.85 HEALTHCARE, BY DISEASE TYPE, 2024 (% SHARE)
86. 6.86 HEALTHCARE, BY DISEASE TYPE, 2024 TO 2035 (USD Billion)
87. 6.87 HEALTHCARE, BY VECTOR SEROTYPE, 2024 (% SHARE)
88. 6.88 HEALTHCARE, BY VECTOR SEROTYPE, 2024 TO 2035 (USD Billion)
89. 6.89 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
90. 6.90 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Billion)
91. 6.91 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  3. 7.2.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.3.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  3. 7.3.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.4.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  3. 7.4.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.5.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  3. 7.5.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.6.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  3. 7.6.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.7.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  3. 7.7.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.8.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  3. 7.8.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.9.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  3. 7.9.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.10.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  3. 7.10.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.11.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  3. 7.11.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.12.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  3. 7.12.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.13.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  3. 7.13.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.14.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  3. 7.14.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.15.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  3. 7.15.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.16.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  3. 7.16.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.17.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  3. 7.17.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.18.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  3. 7.18.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.19.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  3. 7.19.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.20.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  3. 7.20.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.21.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  3. 7.21.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.22.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  3. 7.22.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.23.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  3. 7.23.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.24.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  3. 7.24.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.25.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  3. 7.25.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.26.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  3. 7.26.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.27.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  3. 7.27.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.28.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  3. 7.28.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.29.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  3. 7.29.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY DISEASE TYPE, 2025-2035 (USD Billion)
  2. 7.30.2 BY VECTOR SEROTYPE, 2025-2035 (USD Billion)
  3. 7.30.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Disease Type (USD Billion, 2025-2035)

Hematological Malignancies
Neurological Disorders
Cardiovascular Diseases
Ophthalmic Diseases
Oncology

Healthcare By Vector Serotype (USD Billion, 2025-2035)

AAV1
AAV2
AAV5
AAV6
AAV8
AAV9

Healthcare By Administration Route (USD Billion, 2025-2035)

Intravenous
Intramuscular
Subcutaneous
Intraocular
Intracerebral

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”